Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18071830 | 0.90 | PNMT (0.43) | MEP1BTAAR1 | |
| SCHEMBL8134820 | 0.88 | APOBEC3G (0.37) | GABRA1GABRB2MEP1B | |
| SCHEMBL18584816 | 0.88 | GABRA1 (0.50) | GABRA1GABRB2MEP1BTSHR | |
| SCHEMBL5734027 | 0.87 | TAAR1 (0.39) | MEP1BALDH1A1TAAR1IDO1 | |
| SCHEMBL127091 | 0.87 | TAAR1 (0.39) | MEP1BALDH1A1TAAR1IDO1 | |
| SCHEMBL376927 | 0.85 | TAAR1 (0.37) | GABRA1GABRB2MEP1BTSHRTAAR1 | |
| SCHEMBL30933463 | 0.85 | TAAR1 (0.37) | GABRA1GABRB2MEP1BTSHRTAAR1 | |
| SCHEMBL23369512 | 0.83 | CYP3A4 (0.35) | GABRA1GABRB2MEP1BALDH1A1TSHR | |
| SCHEMBL177422 | 0.83 | MPO (0.38) | GABRA1GABRB2TRPA1ALDH1A1TSHR | |
| SCHEMBL489698 | 0.83 | PNMT (0.41) | TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4653451-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4603484-A2 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-119837855-A | Compounds for the treatment of bacterial infections and for the enhancement of antibiotics | 乔治亚州大学研究基金会 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024165072-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF | 成都纽瑞特医疗科技股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4076420-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114845708-A | Compounds for treating bacterial infections and enhancing antibiotics | 乔治亚州大学研究基金会 | 2022-08-02 | — | — | CN | disclosed |
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| WO-2021127452-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5583238-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0561948-B1 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | UPJOHN CO (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0622373-A1 | Phosphonic acid derivatives useful as anti-inflammatory agents | THE UPJOHN COMPANY (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5360797-A | Bisphosphonic acid derivatives useful as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1994-11-01 | — | — | US | disclosed |
| US-5298498-A | Antiarthritic agents | THE UPJOHN COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0561948-A1 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS. | UPJOHN CO (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010504-A2 | PHOSPHONIC ACID DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | GABRA1 2670/4885GABRB2 2415/4885MEP1B 3474/4885 |
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | BPGM, MYD88, PGLS | GABRA1 1733/4885GABRB2 1043/4885MEP1B 2617/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | GABRA1 1123/4885GABRB2 1313/4885MEP1B 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.